Eltrombopag (Revolade) is a thrombopoietin receptor agonist developed by GlaxoSmithKline, mainly used to treat thrombocytopenia caused by various reasons.

Indications for Eltrombopag (Revolade)

Chronic Immune Thrombocytopenia (ITP)

Eltrombopag is indicated for the treatment of chronic immune (idiopathic) thrombocytopenia in children aged 1 year and older and adults who have an inadequate response to corticosteroids, immunoglobulins, or splenectomy.

This drug should only be used in patient groups where the degree of thrombocytopenia and clinical status increase the risk of bleeding.

Chronic Hepatitis C-Associated Thrombocytopenia

For patients with chronic hepatitis C, eltrombopag can be used to treat thrombocytopenia, enabling patients to initiate and maintain interferon-based treatment regimens.

This drug is only suitable for patients where the degree of thrombocytopenia prevents the initiation of interferon treatment or limits the ability to maintain interferon treatment.

Severe Aplastic Anemia

Eltrombopag is also approved for the treatment of patients with severe aplastic anemia who have an inadequate response to immunosuppressive therapy.

Specifications and Properties of Eltrombopag (Revolade)

Tablets

12.5mg Tablets: Round, biconvex, white film-coated tablets, engraved with "GSMZ1" and "12.5" on one side.

25mg Tablets: Round, biconvex, orange film-coated tablets, engraved with "GSNX3" and "25" on one side.

50mg Tablets: Round, biconvex, blue film-coated tablets, engraved with "GSUFU" and "50" on one side.

75mg Tablets: Round, biconvex, pink film-coated tablets, engraved with "GSFFS" and "75" on one side.

100mg Tablets: Round, biconvex, green film-coated tablets, engraved with "GS1L5" on one side.

Oral Suspension

Eltrombopag is also available as an oral suspension in 25mg sachets. It is a reddish-brown to yellow powder that needs to be reconstituted with water before use.

The suspension is particularly suitable for patients with swallowing difficulties or children. However, it should be noted that the reconstituted suspension must be taken immediately, and any suspension not used within 30 minutes should be discarded.

Storage Methods for Eltrombopag (Revolade)

Storage Conditions

Both eltrombopag tablets and oral suspension should be stored at room temperature (20-25°C), with short-term storage allowed in an environment of 15-30°C.

It is important to keep the drug out of the reach of children and avoid direct sunlight and humid environments.

The oral suspension powder should remain in intact packaging before reconstitution to prevent moisture absorption.